mRNA in exosomas as a liquid biopsy in non-Hodgkin Lymphoma: a multicentric study by the Spanish Lymphoma Oncology Group
Entity
UAM. Departamento de MedicinaPublisher
Impact JournalsDate
2017-03-22Citation
10.18632/oncotarget.16435
Oncotarget 8.31 (2017): 50949-50957
ISSN
1949-2553DOI
10.18632/oncotarget.16435Funded by
This study was supported by grants FIS-PI08/0862, and SAF2010-20750. During this study, V. García received Fundación AECC and RTICC-RD2012/0036/0006 fellowshipsProject
Gobierno de España. FIS-PI08/0862; Gobierno de España. SAF2010-20750Editor's Version
https://doi.org/10.18632/oncotarget.16435Subjects
Exosomes; mRNA; Liquid biopsy; B-cell lymphomas; BCL-6; MedicinaRights
© 2017 Provencio et al.Abstract
Purpose: To determine the feasibility of mRNAs (C-MYC, BCL-XL, BCL-6, NF-κβ,
PTEN and AKT) in exosomes of plasma as a liquid biopsy method for monitoring and
prognostic evolution in B-cell lymphomas.
Patients and Methods: Exosomes were isolated from 98 patients with B-cell
Lymphoma and 68 healthy controls. mRNAs were analyzed by quantitative PCR. An
additional 31 post-treatment samples were also studied.
Results: In the general and follicular lymphoma series, the presence of AKT
mRNA was associated with poor response to rituximab-based treatment. Patients
with first relapse or disease progression showed a lower percentage of PTEN and
BCL-XL mRNA. The presence of BCL-6 mRNA was associated with a high death rate.
The absence of PTEN mRNA in the general series, and presence of C-MYC mRNA in
follicular lymphomas, were associated with short progression-free survival. BCL-6 and
C-MYC mRNA were independent prognostic variables of overall survival. C-MYC mRNA
may provide prognostic information with respect to overall survival. BCL-XL mRNA
and increase of BCL-6 mRNA in post-treatment samples could serve as molecular
monitoring markers.
Conclusions: This is the first large study to evaluate the prognostic and predictive
values of pretreatment tumor-associated mRNA in exosomes. BCL-6 and C-MYC mRNA
positivity in pretreatment samples were predictors of worse PFS compared to patients
with mRNA negativity. C-MYC mRNA positivity was also a statistically significant
predictor of inability to obtain complete response with first-line therapy
Files in this item
Google Scholar:Provencio Pulla, Mariano
-
Rodríguez, Marta
-
Cantos, Blanca
-
Sabín, Pilar
-
Quero, Cristina
-
García-Arroyo, Francisco R.
-
Rueda, Antonio
-
Maximiano, Constanza
-
Rodríguez-Abreu, Delvys
-
Sánchez, Antonio
-
Silva, Javier
-
García, Vanesa
-
GOTEL (Spanish Lymphoma Oncology Group)
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry
Provencio Pulla, Mariano; Sabín, Pilar; Gomez-Codina, Jose; Torrente, María; Calvo de Juan, Virginia; Llanos, Marta; Gumá, Josep; Quero, Cristina; Blasco, Ana; Cruz, Miguel Angel; Aguiar, David; García-Arroyo, Francisco; Lavernia, Javier; Martinez, Natividad; Morales, Manuel B.; Saez-Cusi, Alvaro; Rodriguez, Delvys; Cruz, Luis de la; Sánchez, José Javier; Rueda, Antonio
2017-05-01